Hastim Overview

  • Year Founded
  • 2003

Year Founded

  • Status
  • Private

  • Employees
  • 6


  • Latest Deal Type
  • Angel

  • Latest Deal Amount
  • $800K

  • Investors
  • 1

Hastim General Information


Developer of alternative medicine designed to treat and cure cancer. The company's anticancer treatments focus on strengthening of immune defenses of patients by using nanoparticle and biotechnology methods, enabling doctors to reduce the pain of patients suffering from cancer and attempt to cure cancer.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • Aeroparc Saint Martin
  • 12 rue de Caulet. Bâtiment A06
  • 31300 Toulouse
  • France
+33 05 00 00 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Hastim Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Angel (individual) 17-Jul-2013 $800K 00.000 000.00 Completed Generating Revenue
3. Angel (individual) 09-Dec-2010 00000 00000 000.00 Completed Generating Revenue
2. Product Crowdfunding 01-Jun-2010 $1M Completed Generating Revenue
1. Accelerator/Incubator Completed Generating Revenue
To view Hastim’s complete valuation and funding history, request access »

Hastim Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 0,000 000.000000 0000.0 0000.0 00 0000.0 00.000
Ordinary 0,000 000.000000 0000.00 0000.00 00 0000.00 0.000
To view Hastim’s complete cap table history, request access »

Hastim Patents

Hastim Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4124663-A1 Methods for predicting a response to cancer treatment Pending 29-Jul-2021 0000000000 0
US-20210008187-A1 Autologous cancer vaccines Pending 14-Mar-2018 00000000000
EP-3765067-A1 Autologous cancer vaccines Pending 14-Mar-2018 00000000000
CA-3093576-A1 Autologous cancer vaccines Pending 14-Mar-2018 00000000000
AU-2019235488-A1 Autologous cancer vaccines Pending 14-Mar-2018 A61K39/0011
To view Hastim’s complete patent history, request access »

Hastim Executive Team (2)

Name Title Board Seat Contact Info
Patrick Frayssinet Co-Founder & Deputy Chief Executive Officer
Nicole Rouquet Ph.D Co-Founder, Co-Owner, Président, Directeur Général & Chairman
To view Hastim’s complete executive team members history, request access »

Hastim Board Members (1)

Name Representing Role Since
Nicole Rouquet Ph.D Hastim Co-Founder, Co-Owner, Président, Directeur Général & Chairman 000 0000
To view Hastim’s complete board members history, request access »

Hastim Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Hastim Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Nubbo Accelerator/Incubator 000 0000 000000 0
To view Hastim’s complete investors history, request access »